|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:activities
|
broad-spectrum
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1999
gptkb:FDA
|
|
gptkbp:brand
|
Tequin
|
|
gptkbp:chemical_formula
|
C18 H20 FN3 O4
|
|
gptkbp:class
|
gptkb:fluoroquinolone
quinolone
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
tendon disorders
|
|
gptkbp:discovery_year
|
gptkb:1980s
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:cream
injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
gatifloxacin
|
|
gptkbp:indication
|
skin infections
community-acquired pneumonia
urinary tract infections
acute bacterial sinusitis
|
|
gptkbp:interacts_with
|
gptkb:theophylline
gptkb:warfarin
gptkb:sucralfate
antacids
|
|
gptkbp:lifespan
|
7 to 14 hours
|
|
gptkbp:marketed_as
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:mechanism_of_action
|
inhibits bacterial DNA gyrase
|
|
gptkbp:pharmacokinetics
|
concentration-dependent killing
oral bioavailability 90%
|
|
gptkbp:production_status
|
discontinued
|
|
gptkbp:provides_guidance_on
|
not recommended for children
not recommended for pregnant women
use with caution in elderly patients
|
|
gptkbp:related_products
|
gptkb:ciprofloxacin
gptkb:moxifloxacin
levofloxacin
ofloxacin
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
diarrhea
photosensitivity
tendon rupture
hypersensitivity reactions
QT prolongation
|
|
gptkbp:structure
|
fluorinated derivative of nalidixic acid
|
|
gptkbp:targets
|
bacterial DNA
|
|
gptkbp:used_for
|
bacterial infections
|
|
gptkbp:water_resistance
|
efflux pumps
target site mutations
|
|
gptkbp:weight
|
361.37 g/mol
|
|
gptkbp:withdrawn_year
|
gptkb:2006
|
|
gptkbp:bfsParent
|
gptkb:Zymar
|
|
gptkbp:bfsLayer
|
7
|